FR2786096A1 - Compositions for the prevention and treatment of cellulitis contain plant extracts comprising a sulfur heteroside - Google Patents
Compositions for the prevention and treatment of cellulitis contain plant extracts comprising a sulfur heteroside Download PDFInfo
- Publication number
- FR2786096A1 FR2786096A1 FR9814659A FR9814659A FR2786096A1 FR 2786096 A1 FR2786096 A1 FR 2786096A1 FR 9814659 A FR9814659 A FR 9814659A FR 9814659 A FR9814659 A FR 9814659A FR 2786096 A1 FR2786096 A1 FR 2786096A1
- Authority
- FR
- France
- Prior art keywords
- extract
- composition according
- agent
- prevention
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
-t La présente invention concerne des compositions cosmétiques ouThe present invention relates to cosmetic compositions or
pharmaceutiques permettant la prévention et le traitement des désordres esthétiques et/ou physiopathologiques, plus connus dans le langage commun sous la dénomination de cellulite et utilisant, à titre de principe actif, des produits d'origine naturelle. L'entité clinique appelée cellulite est avant tout considérée comme une conséquence de modifications polyendocriniennes. La pathogénie semble liée à une hyperpolymérisation des mucopolysaccharides et à une rétention hydrique, conduisant à une hyperviscosité de la substance fondamentale puis à un déficit 1o microvasculaire et à des altérations de la perméabilité capillaire. Cet état entraîne une diminution des échanges entre les cellules, les fibres et les vaisseaux, et conduit peu à peu à une modification fibrinoïde des fibres conjonctives, à une compression capillaire avec ralentissement circulatoire, et enfin à une surcharge des adipocytes en triglycérides. Cette situation conduit à la formation de micro- puis de macronodules sous-cutanés qui donnent à la peau pharmaceuticals for the prevention and treatment of aesthetic and / or pathophysiological disorders, better known in common parlance under the name of cellulite and using, as active ingredient, products of natural origin. The clinical entity called cellulite is primarily seen as a consequence of polyendocrine changes. The pathogenesis seems to be linked to a hyperpolymerization of the mucopolysaccharides and to fluid retention, leading to hyperviscosity of the fundamental substance then to a microvascular deficit and to alterations in capillary permeability. This state leads to a decrease in exchanges between cells, fibers and vessels, and gradually leads to a fibrinoid modification of the connective fibers, to capillary compression with circulatory slowing, and finally to an overload of adipocytes with triglycerides. This situation leads to the formation of micro- and then subcutaneous macronodules which give the skin
un aspect capitonné en "peau d'orange". a padded appearance in "orange peel".
De nombreux produits sont disponibles sur le marché, mais ces produits sont sans activité réellement prouvée. Une explication aux insuccès rencontrés pourrait être que les traitements disponibles s'intéressent et se limitent, dans la plupart des cas, à la physiologie de l'adipocyte, puis éventuellement à Many products are available on the market, but these products have no proven activity. One explanation for the failures encountered could be that the treatments available are concerned with and are limited, in most cases, to the physiology of the adipocyte, and then possibly to
l'amélioration de la circulation sanguine. improving blood circulation.
La présente invention repose sur une approche originale selon laquelle il est indispensable de prendre en compte et de traiter la rigidité de la trame conjonctivale. Il est possible ensuite de rétablir la fonctionnalité de la microcirculation, puis en aval de la cascade des événements, contribuer à The present invention is based on an original approach according to which it is essential to take into account and treat the rigidity of the conjunctival framework. It is then possible to restore the functionality of the microcirculation, then downstream of the cascade of events, to contribute to
l'activation de la lipolyse.activation of lipolysis.
Une solution est proposée par l'utilisation d'extraits de plantes contenant des hétérosides soufrés (tels que des glucosinolates) permettant une inhibition de la lysyloxydase et ainsi de la formation des ponts entre fibrilles de collagènes, ponts qui sont à l'origine de la rigidification du milieu et d'un emprisonnement A solution is proposed by the use of plant extracts containing sulfur heterosides (such as glucosinolates) allowing an inhibition of lysyloxydase and thus of the formation of bridges between collagen fibrils, bridges which are at the origin of the stiffening of the environment and imprisonment
des cellules adipeuses hypertrophiées. enlarged fat cells.
Les fibres de collagène sont normalement stabilisées par la formation de liaisons covalentes sur des résidus lysine et OH-lysine. Une désamination oxydative des résidus lysyle et OH-lysyle par la lysyl oxydase précède la formation de ces pontages. L'inhibition de la lysyloxidase, en diminuant la formation des liaisons covalentes, permet de diminuer la rigidité des fibres de Collagen fibers are normally stabilized by the formation of covalent bonds on lysine and OH-lysine residues. Oxidative deamination of lysyl and OH-lysyl residues by lysyl oxidase precedes the formation of these bridges. The inhibition of lysyloxidase, by reducing the formation of covalent bonds, makes it possible to reduce the rigidity of the fibers
collagène et contribue à faciliter les échanges tissulaires. collagen and helps facilitate tissue exchange.
La présente invention a donc plus particulièrement pour objet une composition cosmétique ou pharmaceutique pour la prévention et le traitement topique de la cellulite, comprenant à titre de principe actif une quantité efficace d'un extrait de plante contenant des hétérosides soufrés, dans une base The present invention therefore more particularly relates to a cosmetic or pharmaceutical composition for the prevention and topical treatment of cellulite, comprising, as active principle, an effective amount of a plant extract containing sulfur heterosides, in a base
cosmétique ou pharmaceutique pour application topique. cosmetic or pharmaceutical for topical application.
La présente invention a également pour objet un procédé pour la prévention et le traitement topique de la cellulite, qui consiste à appliquer sur la peau une quantité efficace d'un extrait de plantes contenant des hétérosides The present invention also relates to a method for the prevention and topical treatment of cellulite, which consists in applying to the skin an effective amount of a plant extract containing heterosides
soufrés.sulfur.
L'extrait de plante utilisé dans la présente invention est notamment choisi parmi les plantes contenant des glucosinolates telles que: * dans la famille des Tropaeolacées: Tropaeolum majus (Capucine) * dans la famille des Pentadiplandracées: Pentadiplandra brazzeana * dans la famille des Crucifères: Brassica barrelieri, Capsella bursa-pastoris, Diplotaxis catholica, Erysimum allionii, Raphanus sativus, Sinapis arvensis; a dans la famille des Moringacées: Moringa oleifera; * dans la famille des Phytolaccacées: Phytolacca americana; The plant extract used in the present invention is chosen in particular from plants containing glucosinolates such as: * in the Tropaeolaceae family: Tropaeolum majus (Capucine) * in the Pentadiplandraceae family: Pentadiplandra brazzeana * in the Cruciferous family: Brassica barrelieri, Capsella bursa-pastoris, Diplotaxis catholica, Erysimum allionii, Raphanus sativus, Sinapis arvensis; a in the Moringaceae family: Moringa oleifera; * in the Phytolaccaceae family: Phytolacca americana;
* dans la famille des Resedacées: Reseda phyteum. * in the Resedaceae family: Reseda phyteum.
Les compositions selon l'invention peuvent avantageusement contenir un agent favorisant la microcirculation. Comme agents de ce type, on peut citer des The compositions according to the invention may advantageously contain an agent promoting microcirculation. As agents of this type, mention may be made of
extraits de Gingko biloba, ruscus, mélilot, vigne rouge, viburnum. extracts of Gingko biloba, ruscus, sweet clover, red vine, viburnum.
Les compositions selon l'invention peuvent en outre contenir avantageusement un agent d'activation de la lipolyse. Comme agents de ce type, on peut citer les extraits de Lierre terrestre (Glechoma), de racine d'Angélique, d'extrait de Paullinia, de Maté ou encore des bases xanthiques telles que The compositions according to the invention may also advantageously contain an agent for activating lipolysis. As agents of this type, mention may be made of extracts of ground ivy (Glechoma), of Angelica root, of Paullinia extract, of Mate or also of xanthic bases such as
cafeine, théobromine et théophylline. caffeine, theobromine and theophylline.
Les compositions cosmétiques ou pharmaceutiques selon l'invention peuvent en outre contenir éventuellement toutes les substances connues ayant des propriétés bienfaisantes sur les téguments et particulièrement pour leur activité cosmétique ou pharmaceutique dans les soins des peaux de toutes natures, en particulier celles manifestant une tendance aux surcharges graisseuses et à la formation de cellulite. Elles peuvent contenir des antiseptiques, des comédolytiques, des antiséborrhéiques, des parfums, des The cosmetic or pharmaceutical compositions according to the invention may also optionally contain all the known substances having beneficial properties on the integuments and particularly for their cosmetic or pharmaceutical activity in the care of skin of all kinds, in particular those manifesting a tendency to overloads. greasy and cellulite formation. They may contain antiseptics, comedolytics, antiseborrheics, perfumes,
1o conservateurs et des colorants.1o preservatives and dyes.
Les compositions cosmétiques ou pharmaceutiques selon l'invention peuvent se présenter sous toutes les formes topiques utilisées en pharmacie ou en cosmétologie: crème ou gel en pots ou en tubes, lait, lotion en flacon de verre ou de plastique, en ampoules, microinjections ou en flacons doseurs, The cosmetic or pharmaceutical compositions according to the invention can be in any topical form used in pharmacy or in cosmetology: cream or gel in jars or in tubes, milk, lotion in glass or plastic bottle, in ampoules, microinjections or in dosing bottles,
compresses imprégnées, emplâtres, patch-tests, timbres. impregnated compresses, plasters, patch tests, patches.
Pour chaque forme particulière, on a recours à des excipients appropriés. For each particular form, appropriate excipients are used.
Ces excipients doivent avoir toutes les qualités habituellement demandées. A titre d'exemples, on peut citer: le propylène glycol, la glycérine, I'alcool cétylique, les polyols, les phospholipides mis dans des liposomes ou non, les huiles végétales, animales, minérales, les mouillants, les épaississants, These excipients must have all the qualities usually required. By way of examples, there may be mentioned: propylene glycol, glycerin, cetyl alcohol, polyols, phospholipids put in liposomes or not, vegetable, animal, mineral oils, wetting agents, thickeners,
stabilisants et émulsionnants couramment utilisés. commonly used stabilizers and emulsifiers.
Les différentes formes cosmétiques ou médicamenteuses mentionnées ci- The different cosmetic or medicinal forms mentioned above
dessus sont obtenues selon les méthodes utilisées dans ce domaine. above are obtained according to the methods used in this field.
Procédé d'obtention et teneur en cilucosinates Parmi les plantes citées, on peut retenir tout particulièrement les parties aériennes de Capucine pour obtenir un extrait utilisable dans la formulation des produits. Tout procédé entraînant les glucosinolates peut être utilisé, et par exemple: les parties aériennes de Capucine sont broyées puis extraites avec dix fois leur poids de solvant (tel que l'éthanol à 60 %). I'extraction est menée sous reflux, sous agitation pendant au moins une heure. Après refroidissement, la Capucine broyée est séparée de la solution éthanolique par essorage. Cette dernière est concentrée sous pression réduite à 60 C jusqu'à obtention d'une Process for obtaining and content of cilucosinates Among the plants mentioned, it is possible to retain very particularly the aerial parts of Nasturtium to obtain an extract which can be used in the formulation of the products. Any process involving glucosinolates can be used, for example: the aerial parts of Capucine are ground and then extracted with ten times their weight of solvent (such as 60% ethanol). The extraction is carried out under reflux, with stirring for at least one hour. After cooling, the crushed nasturtium is separated from the ethanolic solution by wringing. The latter is concentrated under reduced pressure at 60 C until a
solution contenant, au maximum, 1000 ppm d'éthanol. solution containing, at most, 1000 ppm of ethanol.
Pour obtenir une telle norme, on peut séparer en cours de concentration de l'eau, qui sera évaporée dans un second temps. L'évaporation est menée jusqu'à obtention de deux fois le poids de Capucine extrait. On ajoute enfin à ce To obtain such a standard, water can be separated during concentration, which will then be evaporated. Evaporation is carried out until twice the weight of nasturtium extract is obtained. Finally we add to this
concentrat 70 % d'alkyl éther sulfate de triéthanolamine. 70% alkyl ether sulfate triethanolamine concentrate.
La concentration en glucosinolates peut être comprise entre 0,1 et 5 % en poids dans l'extrait et l'extrait peut être incorporé dans les compositions à raison The concentration of glucosinolates can be between 0.1 and 5% by weight in the extract and the extract can be incorporated into the compositions in the right manner
io de 0,5 à 10 % en poids.io from 0.5 to 10% by weight.
Activité sur la yIvsyloxydase L'activité des extraits de plantes et en particulier de l'extrait de capucine sur l'inhibition de la lysyloxydase a été déterminée selon la méthode décrite par Guanmei Liu, Kaliappanadar Nellaiappan, and Herbert M. Kagan "Irreversible Inhibition of Lysyl Oxidase by Homocysteine Thiolactone and its Selenium and Oxygen Analogues", The Journal of Biological Chemistry, vol. 272, n 51, issue of December 19, pp. 32370-32377, 1997: Cinq extraits différents ont été examinés afin de déterminer leur effet sur I'activité de la lysyloxydase. Chaque produit en solution a été testé à deux dilutions en duplicate, dans des essais de l'activité d'une quantité constante de lysyloxydase purifiée d'aorte bovine, contre un substrat de tropoélastine préparé biologiquement. Le substrat a été marqué par de la 1-[4,5-3H]lysine dans un Activity on yIsyloxidase The activity of plant extracts and in particular of nasturtium extract on the inhibition of lysyloxidase was determined according to the method described by Guanmei Liu, Kaliappanadar Nellaiappan, and Herbert M. Kagan "Irreversible Inhibition of Lysyl Oxidase by Homocysteine Thiolactone and its Selenium and Oxygen Analogues ", The Journal of Biological Chemistry, vol. 272, n 51, issue of December 19, pp. 32370-32377, 1997: Five different extracts were examined to determine their effect on the activity of lysyloxidase. Each product in solution was tested at two dilutions in duplicate, in tests for the activity of a constant amount of purified bovine aortic lysyloxidase, against a biologically prepared tropoelastin substrate. The substrate was labeled with 1- [4,5-3H] lysine in a
système exprimé par E. coli.system expressed by E. coli.
La [3H]-tropoélastine a été purifiée et des aliquotes de 125.000 cpm ont été ajoutés dans chaque tube comme substrat pour la lysyloxydase en présence ou en absence de dilutions des différents extraits. L'oxydation de la peptidyl lysine par la lysyloxydase induit la perte du tritium du carbone 5 qui est ensuite The [3H] -tropoelastine was purified and aliquots of 125,000 cpm were added to each tube as a substrate for the lysyloxidase in the presence or in the absence of dilutions of the various extracts. The oxidation of peptidyl lysine by lysyloxidase induces the loss of carbon 5 tritium which is then
isolé du milieu et compté en [3H]H20, comme indice de l'activité enzymatique. isolated from the medium and counted in [3H] H2O, as an index of the enzymatic activity.
Toutes les données ont été corrigées du bruit de fond non enzymatique de libération du tritium (négligeable) et pour des effets non spécifiques des extraits All data have been corrected for non-enzymatic background noise in the release of tritium (negligible) and for non-specific effects of the extracts
sur le substrat en l'absence de lysyloxydase exogène (négligeable). on the substrate in the absence of exogenous lysyloxidase (negligible).
Les résultats obtenus sont les suivants: Activité Echantillon Dilution enzymatique: Activité libération 3H20 % cpm/2h. Contrôle lysyloxydase bovine 1047 + 69 100 Extrait 1: 1:50 436 + 95 41,6 Bourse-à-Pasteur 1:5 42 + 42 4 Extrait 2: 1:50 510 + 9 48,7 Capucine 1:5 16 +4 1,5 Extrait 3: 1:50 0 + 0 0 Capucine 1:5 0 + 17 0 Extrait 4: 1:50 812 + 57 77,6 Radis 1:5 147 + 50 14 Ainsi, I'extrait 3 permet d'inhiber complètement l'activité de la lysyloxydase. The results obtained are as follows: Sample activity Enzymatic dilution: 3H20% cpm / 2h release activity. Bovine lysyloxidase control 1047 + 69 100 Extract 1: 1:50 436 + 95 41.6 Bourse-à-Pasteur 1: 5 42 + 42 4 Extract 2: 1:50 510 + 9 48.7 Nasturtium 1: 5 16 +4 1.5 Extract 3: 1:50 0 + 0 0 Nasturtium 1: 5 0 + 17 0 Extract 4: 1:50 812 + 57 77.6 Radish 1: 5 147 + 50 14 Thus, extract 3 allows completely inhibit lysyloxidase activity.
EXEMPLEEXAMPLE
On donnera ci-après un exemple de composition selon l'invention: Composition de type gel - extrait de guarana 6,25 g - extrait de capucine 3,00 g - extrait de viburnum 1,00 g - éthanol 27 % en volume - parfum mûre An example of a composition according to the invention will be given below: Gel-type composition - guarana extract 6.25 g - nasturtium extract 3.00 g - viburnum extract 1.00 g - ethanol 27% by volume - perfume blackberry
- excipient gélifié q.s.p. 100 g.- gelled excipient q.s.p. 100g.
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9814659A FR2786096B1 (en) | 1998-11-20 | 1998-11-20 | COMPOSITION FOR THE PREVENTION AND TOPICAL TREATMENT OF CELLULITE |
PCT/FR1999/002857 WO2000030604A1 (en) | 1998-11-20 | 1999-11-19 | Composition for preventing and treating cellulitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9814659A FR2786096B1 (en) | 1998-11-20 | 1998-11-20 | COMPOSITION FOR THE PREVENTION AND TOPICAL TREATMENT OF CELLULITE |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2786096A1 true FR2786096A1 (en) | 2000-05-26 |
FR2786096B1 FR2786096B1 (en) | 2002-10-18 |
Family
ID=9533012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9814659A Expired - Fee Related FR2786096B1 (en) | 1998-11-20 | 1998-11-20 | COMPOSITION FOR THE PREVENTION AND TOPICAL TREATMENT OF CELLULITE |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2786096B1 (en) |
WO (1) | WO2000030604A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064177A1 (en) * | 2000-02-28 | 2001-09-07 | Henkel Kommanditgesellschaft Auf Aktien | Use of flavones or isoflavones for the treatment of cellulite |
WO2002096448A1 (en) * | 2001-05-29 | 2002-12-05 | Philippe Jean Louis Thurot | Composition for oral or corporeal hygiene or for health comprising seeds or ground material or protein extracts based on seeds of a plant of the genus moringa |
FR2965483A1 (en) * | 2010-10-04 | 2012-04-06 | Silab Sa | COSMETIC USE OF A TROPAEOLUM MAJUS EXTRACT AS AN ACTIVE INGREDIENT TO PROMOTE OXYGENATION OF SKIN TISSUE |
WO2022123167A1 (en) * | 2020-12-11 | 2022-06-16 | Laboratoires De Biologie Vegetale Yves Rocher | Cosmetic use of a combination of nasturtium and tetraselmis extracts |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030091518A1 (en) * | 1999-12-20 | 2003-05-15 | Gilles Pauly | Cosmetic and/or pharmaceutical preparations |
US7744937B2 (en) | 2005-08-09 | 2010-06-29 | Kraft Foods Global Brands Llc | Chemoprotectants from crucifer seeds and sprouts |
FR2893252B1 (en) * | 2005-11-17 | 2008-02-15 | Engelhard Lyon Sa | VEGETABLE EXTRACTS STIMULATING HAS2 |
EP2678029B1 (en) | 2011-02-22 | 2016-11-09 | Caudill Seed Company, Inc. | Spray dried myrosinase and use to produce isothiocyanates |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2666228A1 (en) * | 1990-08-28 | 1992-03-06 | Roux Nicole | Composition for the treatment of excessive weight and/or of cellulite |
FR2769837A1 (en) * | 1997-10-17 | 1999-04-23 | Bio Sphere 99 Lab | Dietetic and cosmetic compositions containing a pectin and a carotenoid, glucosinolate, and/or sulforaphan |
-
1998
- 1998-11-20 FR FR9814659A patent/FR2786096B1/en not_active Expired - Fee Related
-
1999
- 1999-11-19 WO PCT/FR1999/002857 patent/WO2000030604A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2666228A1 (en) * | 1990-08-28 | 1992-03-06 | Roux Nicole | Composition for the treatment of excessive weight and/or of cellulite |
FR2769837A1 (en) * | 1997-10-17 | 1999-04-23 | Bio Sphere 99 Lab | Dietetic and cosmetic compositions containing a pectin and a carotenoid, glucosinolate, and/or sulforaphan |
Non-Patent Citations (3)
Title |
---|
BENAIGES ET AL.: "Study of the refirming effect of a plant complex", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, vol. 20, no. 4, August 1998 (1998-08-01), pages 223 - 233 * |
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 93:191886, XP002115307 * |
DATABASE STN EMBASE 1 January 1900 (1900-01-01), XP002115306, Database accession no. 1998391218 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064177A1 (en) * | 2000-02-28 | 2001-09-07 | Henkel Kommanditgesellschaft Auf Aktien | Use of flavones or isoflavones for the treatment of cellulite |
WO2002096448A1 (en) * | 2001-05-29 | 2002-12-05 | Philippe Jean Louis Thurot | Composition for oral or corporeal hygiene or for health comprising seeds or ground material or protein extracts based on seeds of a plant of the genus moringa |
FR2825267A1 (en) * | 2001-05-29 | 2002-12-06 | Philippe Jean Louis Thurot | COMPOSITIONS FOR ORAL OR BODY HYGIENE OR CLEANLINESS OR HEALTH COMPRISING SEEDS OR A BROYAT OF SEEDS OR AN EXTRACT OF SEEDS OF THE GENINGA TYPE |
FR2965483A1 (en) * | 2010-10-04 | 2012-04-06 | Silab Sa | COSMETIC USE OF A TROPAEOLUM MAJUS EXTRACT AS AN ACTIVE INGREDIENT TO PROMOTE OXYGENATION OF SKIN TISSUE |
WO2012045974A3 (en) * | 2010-10-04 | 2012-10-18 | Societe Industrielle Limousine D'application Biologique | Cosmetic use of a tropaeolum majus extract as an active principle for promoting the oxygenation of skin tissue |
WO2022123167A1 (en) * | 2020-12-11 | 2022-06-16 | Laboratoires De Biologie Vegetale Yves Rocher | Cosmetic use of a combination of nasturtium and tetraselmis extracts |
FR3117369A1 (en) * | 2020-12-11 | 2022-06-17 | Laboratoires De Biologie Vegetale Yves Rocher | COSMETIC USE OF A COMBINATION OF Nasturtium AND TETRASELMIS EXTRACTS |
Also Published As
Publication number | Publication date |
---|---|
WO2000030604A1 (en) | 2000-06-02 |
FR2786096B1 (en) | 2002-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1178209A (en) | Slenderizing and anti-cellulite cosmetic composition of vegetable extract containing saponines, arnica montana extract, and cola bean extract and method of use | |
EP0236218B1 (en) | Cosmetic compositions containing an extract of silybum marianum fruits | |
CA2328586A1 (en) | Use of 3,3',5,5'-tetrahydroxystilbene as an anti-glycation agent | |
EP0755672B1 (en) | Silicon composition containing a water-sensitive agent | |
FR2746316A1 (en) | NEW COSMETOLOGICAL OR DERMATOLOGICAL COMPOSITIONS | |
FR2802425A1 (en) | Cosmetic compositions for combating aging of the skin or exoskeleton contain extract of Vaccinium genus plant as glycation inhibitor | |
EP0179675B1 (en) | Lipid compositions favouring the growth of phaners, and cosmetic products containing them | |
FR2535201A1 (en) | COSMETIC PREPARATIONS PROMOTING THE NUTRITION OF THE SKIN AND THE PILARY FOLLICLES THAT IT CONTAINS | |
EP0248701B1 (en) | Liquid product for the esthetic treatment of the skin, and process for its preparation | |
FR2786096A1 (en) | Compositions for the prevention and treatment of cellulitis contain plant extracts comprising a sulfur heteroside | |
CA1091581A (en) | Cosmetic composition against cellulitis and for slenderizing | |
WO2003026605A2 (en) | Cosmetic composition for human skin and hair care | |
FR2791255A1 (en) | Anti-androgenic compositions contain a vegetable-based complex derived from sabal, marrow and epilobium, for prevention of hair regrowth, loss of hair, and seborrhea | |
EP0907353B1 (en) | Slimming cosmetic composition containing a chrysanthellum indicum extract | |
FR2487674A1 (en) | COSMETIC PRODUCT WITH REGENERATIVE EFFECTS ON SKIN AND MUSCLES AND PROCESS FOR THE PREPARATION OF SAID COSMETIC PRODUCT | |
FR2848846A1 (en) | COSMETIC USE OF ASCORBIC ACID DERIVATIVES AS BLANCHING AGENTS | |
FR2770228A1 (en) | Proanthocyanidine oligomer concentrates obtained by fermenting Schinopsis lorenzii extract | |
FR2761888A1 (en) | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING ANDIROBA EXTRACT | |
FR2863492A1 (en) | USE OF AQUAGLYCEROPORIN MODULATORS AS SLIMMING | |
EP0277455A1 (en) | Hair composition | |
FR2820973A1 (en) | COMPOSITION COMPRISING VITAMIN C PREPARED DURING APPLICATION, USE OF ENZYMES FOR THE FORMATION OF VITAMIN C FOR TOPICAL USE AND COSMETIC PROCESSING METHOD | |
BR112012025740B1 (en) | Cosmetic preparation, and use of dihydrodesidrodi-isoeugenol | |
FR2759910A1 (en) | Cosmetic and dermo-pharmaceutical use of extracts of Kigelia africana | |
FR2750332A1 (en) | Topical skin composition to treat or prevent cellulite | |
WO2003002085A1 (en) | Use of purified, water-soluble xylans extracted from palmaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20120731 |